We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

JWEL:NASDAQJowell Global Ltd. Analysis

Data as of 2026-06-18 - not real-time

$2.65

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

JWEL trades at $2.65, far below its DCF fair value of roughly $39, indicating a massive valuation gap. Technical signals are mixed: the 20‑day SMA (2.37) sits just below the price, the 50‑day SMA (2.41) is slightly above, and the MACD histogram is positive with a bullish signal line, while the RSI hovers around 60, suggesting modest momentum but no overbought condition. Fundamentally, the company shows strong top‑line growth (revenue up 88%) yet remains unprofitable, with negative operating and profit margins, a negative EPS of -2.87, and a high max drawdown of ~46%. Volume is decreasing, and the 30‑day volatility exceeds 80%, underscoring a fragile price environment.
Given the ultra‑low market cap (~$6.3 M) and thin trading, liquidity risk is pronounced, and exposure to the Chinese consumer‑cyclical sector adds regulatory and geographic uncertainties. The stock’s low beta suggests limited systematic risk, but the combination of negative cash flows, high debt‑to‑equity, and a lack of dividend support a cautious stance despite the apparent undervaluation.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • Bullish MACD and RSI near 60 indicate short‑term momentum
  • Decreasing volume and high volatility raise execution risk
  • Negative earnings and cash flow limit upside potential

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • DCF valuation suggests >1,400% upside
  • Revenue growth of 88% provides a potential turnaround catalyst
  • Low beta and modest price‑to‑sales ratio support a value‑oriented entry

Long Term

> 3 years
Cautious
Model confidence: 3/10

Key Factors

  • Sustained operating losses and negative ROE
  • High max drawdown and thin liquidity
  • Exposure to Chinese regulatory and consumer‑cyclical headwinds

Key Metrics & Analysis

Financial Health

Revenue Growth87.80%
Profit Margin-3.81%
ROE-44.27%
ROA-13.15%
Debt/Equity13.44
P/B Ratio0.5
Op. Cash Flow$-1530441
Free Cash Flow$2.6M

Technical Analysis

TrendNeutral
RSI59.9
Support$2.12
Resistance$3.00
MA 20$2.37
MA 50$2.41
MA 200$2.19
MACDBullish
VolumeDecreasing
Fear & Greed Index88.5

Valuation

Fair Value$39.59
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.44
Volatility82.41%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.